Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Cumberland Pharmaceuticals Adds Vibativ®


 
A.J. Kazimi

Cumberland Pharmaceuticals recently announced the addition of Vibativ® (telavancin) to its growing product lineup. The Nashville-headquartered specialty pharmaceutical company entered into a definitive agreement to acquire Vibativ from Theravance Biopharma in the fourth quarter of 2018.

The FDA-approved injectable antibiotic is used for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin & skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

"Vibativ is a lifesaving product for certain difficult to treat infections, and we are honored to be selected to acquire and transition the brand to our existing hospital acute care infrastructure," said Cumberland Pharmaceuticals CEO A.J. Kazimi, "Our immediate plan for Vibativ is to ensure a smooth transition of the product supply and medical support to current users of the brand. We will then launch our hospital promotion and medical initiatives to help ensure that the product is available to the patients who need it. We are very optimistic about the opportunity that Vibativ will offer Cumberland."

The financial terms include a $20 million payment to Theravance Biopharma upon closing, a $5 million additional payment in early 2019, and tiered royalties of up to 20 percent on future U.S. net product sales. Under the terms of the agreement, Cumberland will assume full responsibility for the product including its marketing, distribution, manufacturing and regulatory activities. Kazimi said Cumberland expects to selectively expand its sales force, medical science liaison and corporate teams to ensure the needed support of Vibativ, as well as its oncology and acute care brands.

 
Share:

Related Articles:


Recent Articles

AMA Issues Checklist for the Transition to E/M Office Visit Changes

The American Medical Association (AMA) is helping physician practices integrate fundamental changes to the coding and documentation of evaluation and management (E/M) office visit services that account for nearly $23 billion in Medicare spending.

Read More

AHA's Maryjane Wurth To Retire In 2020; Michelle Hood To Join The Association

Maryjane Wurth, the American Hospital Association's (AHA) executive vice president and chief operating officer (COO), will retire next year after a long and distinguished career in the hospital association field.

Read More

Tennessee Sees Fewer Infant Deaths In 2018

Infant Mortality Data Dashboard Now Available

Read More

Amedisys Expanding Commitment to End-of-Life Care for Veterans

Third Largest Hospice Provider Cared for 5,540 Dying Veterans Last Year

Read More

AMA Applauds Relief from Documentation Burden in New Medicare Rule

Many physicians will have reduced documentation beginning in 2021

Read More

Oncology Innovation in Nashville

From personalized medicine to innovation in GI care, Middle Tennessee oncology leaders share promising news.

Read More

Critical Insights into Nashville Health

For the first time in nearly two decades, Nashville has a countywide assessment providing insights into the health and well-being of the community.

Read More

Physician Spotlight: Leading with Compassion

Hospice care is so much more than simply pain management. Compassus CMO Dr. Kurt Merkelz focuses on helping patients live fully until the end.

Read More

The Oncology Care Model Value Proposition

The American Journal of Managed Care® hosts meetings across the country to help oncology practices understand and navigate the value-based care landscape at the intersection of quality and efficiency.

Read More

Tennessee Falling Short on Cancer-Fighting Public Policies

A 2019 ACS CAN report shows the state is falling short on public policies to fight cancer.

Read More

Email Print
 
 

 

 


Tags:
Cumberland Pharmaceuticals, Drug-Resistant Infection, Gram-Positive Bacterial Infection, HABP/VABP, Hospital-Aquired and Ventilator-Associated Bacterial Pneumonia, Injectable Antibiotic, MRSA, Telavancin, Vibativ
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: